Literature DB >> 22187120

Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.

Kazumasa Fujitani1, Masayuki Mano, Motohiro Hirao, Yoshinori Kodama, Toshimasa Tsujinaka.   

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NAC) has been attempted as a means of improving survival of potentially resectable advanced gastric cancer (AGC). In the course of exploring the most promising NAC regimen, a superior surrogate marker reflecting overall survival (OS) is necessary. We investigated prognostic factors in AGC patients who underwent NAC followed by gastric resection and evaluated whether histologic response to NAC was predictive of survival.
METHODS: Seventy consecutive patients with gastric cancer treated with NAC followed by surgical resection between Jan 1, 2000, and Dec 31, 2009, at Osaka National Hospital were identified from a prospective database. Prognostic factors for OS were investigated by univariate and multivariate analyses.
RESULTS: Median survival time for all patients was 668 days after surgical resection. Age less than 65 years (hazard ratio 0.463, 95% confidence interval 0.244-0.879) and pathologic nodal stage of N0-1 (hazard ratio 0.318, 95% confidence interval 0.160-0.635) were identified as significant independent prognostic factors for longer OS, whereas graded histologic response of primary tumor to NAC was statistically significant on univariate analysis, but not on multivariate analysis, as a prognostic factor.
CONCLUSIONS: Posttherapy nodal status, not graded histologic response, predicts survival after NAC for AGC and could serve as a reliable surrogate marker for OS in the course of exploring the most promising regimen for NAC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22187120     DOI: 10.1245/s10434-011-2165-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Rosa Berenato; Luca Turati; Alessia Mennitto; Francesca Steccanella; Marta Caporale; Pierpaolo Dallera; Filippo de Braud; Ezio Pezzica; Maria Di Bartolomeo; Giovanni Sgroi; Vincenzo Mazzaferro; Filippo Pietrantonio; Sandro Barni
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 2.  What make differences in the outcome of adjuvant treatments for resected gastric cancer?

Authors:  Toshifusa Nakajima; Masashi Fujii
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

3.  Tumor Regression Grade in Gastric Cancer After Preoperative Therapy.

Authors:  Naruhiko Ikoma; Jeannelyn S Estrella; Mariela Blum Murphy; Prajnan Das; Bruce D Minsky; Paul Mansfield; Jaffer A Ajani; Brian D Badgwell
Journal:  J Gastrointest Surg       Date:  2020-06-15       Impact factor: 3.452

4.  Does histology really influence gastric cancer prognosis?

Authors:  Carrie Luu; Ram Thapa; Katherine Woo; Domenico Coppola; Khaldoun Almhanna; Jose M Pimiento; Dung-Tsa Chen; Daissy Dominguez Marquez; Pamela J Hodul
Journal:  J Gastrointest Oncol       Date:  2017-12

5.  Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Where we Stand; An Italian Single Center Perspective.

Authors:  Elisabetta Marino; Luigina Graziosi; Annibale Donini
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

6.  Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas.

Authors:  T Schmidt; L Sicic; S Blank; K Becker; W Weichert; T Bruckner; T Parakonthun; R Langer; M W Büchler; J-R Siewert; F Lordick; K Ott
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

7.  A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer.

Authors:  Xiang Wang; Lin Zhao; Hongfeng Liu; Dingrong Zhong; Wei Liu; Guangliang Shan; Fen Dong; Weisheng Gao; Chunmei Bai; Xiaoyi Li
Journal:  Br J Cancer       Date:  2016-05-12       Impact factor: 7.640

8.  Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.

Authors:  Patricia Martin-Romano; Jose J Sola; Juan A Diaz-Gonzalez; Ana Chopitea; Yohana Iragorri; Fernando Martínez-Regueira; Mariano Ponz-Sarvise; Leire Arbea; Jose C Subtil; David Cano; Lucia Ceniceros; Jairo Legaspi; Jose Luis Hernandez; Javier Rodríguez
Journal:  Br J Cancer       Date:  2016-08-18       Impact factor: 7.640

9.  Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection.

Authors:  Yongkun Sun; Lin Yang; Chengfeng Wang; Dongbing Zhao; Jianqiang Cai; Wenbin Li; Wen Zhang; Jing Huang; Aiping Zhou
Journal:  Oncotarget       Date:  2017-09-06

Review 10.  Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification.

Authors:  Kazuhiro Yoshida; Kazuya Yamaguchi; Naoki Okumura; Toshiyuki Tanahashi; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2015-12-07       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.